Europe Medical Cannabis Market Growth Driven By Regulatory Advances In 2025

(MENAFN- IMARC Group) The Europe medical cannabis market is witnessing unprecedented growth, driven by expanding legalization frameworks, increasing patient demand, and broadening therapeutic use cases across the region. According to the IMARC Group, the market was valued at USD 2,586.1 million in 2024 and is projected to reach USD 12,652.9 million by 2033 , growing at a robust CAGR of 18.33% from 2025 to 2033 . Germany currently holds the largest share, accounting for 26.7% of the market in 2024 , backed by supportive reforms and a maturing cannabis infrastructure.

Key Highlights

• Market size (2024): USD 2,586.1 Million
• Forecast (2033): USD 12,652.9 Million
• CAGR (2025–2033): 18.33%
• Germany market share (2024): 26.7%
• Legal reforms and rising patient volumes driving medical cannabis adoption
• Advanced cultivation and extraction technologies boosting pharmaceutical-grade output
• Key companies operating in the European medical cannabis market include Canopy Growth Corporation, Aurora Cannabis Inc., Tilray, Inc., Demecan GmbH, Panaxia Pharmaceutical Industries Ltd, Little Green Pharma, Cannamedical Pharma GmbH, Sapphire Medical, Althea Group, Bedrocan International, etc.

How Is Legalization Transforming the Medical Cannabis Market in Europe?

Europe's evolving cannabis landscape is being reshaped by progressive legalization and healthcare integration. In countries like Germany, medical cannabis is becoming more accessible due to:

• Decriminalization and regulatory clarity for physicians and patients
• Surging import volumes and local production to meet rising demand
• Integration of cannabis-based treatments in therapeutic areas such as chronic pain, cancer, epilepsy, and mental health

Combined with strong public awareness and physician education programs, the region has witnessed consistent year-on-year growth in prescriptions and patient registrations.

Key Market Trends and Drivers

• Legalization Momentum: Ongoing regulatory approvals and de-scheduling of cannabis in major markets like Germany are expanding access and legitimacy.
• Therapeutic Expansion: Physicians are prescribing cannabis for a growing range of chronic and neurological conditions.
• Investment in R&D: Companies are investing in clinical research to develop targeted and high-efficacy formulations.
• Advanced Cultivation & Extraction: High-tech indoor cultivation and pharmaceutical-grade extraction methods are ensuring consistent product quality.
• Strategic Partnerships: M&A activity, cross-border collaborations, and vertical integration are helping companies scale across Europe.

Download a sample copy of the report: https://www.imarcgroup.com/europe-medical-cannabis-market/requestsample

Europe Medical Cannabis Industry Segmentation:

Analysis by Species:

• Indica
• Sativa
• Hybrid

Analysis by Derivative:

• Cannabidiol (CBD)
• Tetrahydrocannabinol (THC)
• Others

Analysis by Application:

• Cancer
• Arthritis
• Migraine
• Epilepsy
• Others

Analysis by End Use:

• Pharmaceutical Industry
• Research and Development Centers
• Others

Analysis by Route of Administration:

• Oral Solutions and Capsules
• Smoking
• Vaporizers
• Topicals
• Others

Analysis by Country:

• Germany
• France
• United Kingdom
• Italy
• Spain
• Others

Latest Developments in the Industry

• In April 2024 , Germany officially removed cannabis from its narcotics list, allowing easier prescribing and dispensing for medical purposes-resulting in a significant increase in import volumes.
• At the Medical Cannabis Europe Conference 2025 (Amsterdam, June) , over 90 exhibitors from 25 countries showcased clinical-grade products, automation in cultivation, and cannabinoid-based pharmaceuticals. Several collaboration deals and MOUs were announced.
• Multiple start-ups and global cannabis brands are setting up local production hubs in Germany , leveraging favorable regulatory conditions and public health demand.
• Investment in patient education platforms and e-prescription systems is helping streamline medical access and physician-patient engagement.

MENAFN05082025004122016232ID1109885827